FK 506 affects platelet aggregation in vitro.
暂无分享,去创建一个
[1] P. Mcmaster,et al. FK 506 in transplantation. , 1993, Transplantation Proceedings.
[2] A. Oriente,et al. Anti-inflammatory effect of FK-506 on human skin mast cells. , 1992, The Journal of investigative dermatology.
[3] N. Perico,et al. THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE , 1992, Transplantation.
[4] A. Oriente,et al. Characterization of the anti-inflammatory effect of FK-506 on human mast cells. , 1991, Journal of immunology.
[5] A. E. Trezíse,et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. , 1991, Transplantation proceedings.
[6] N. Sigal,et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. , 1991, Biochemical pharmacology.
[7] G. Schultz,et al. The superoxide-forming NADPH oxidase of phagocytes. An enzyme system regulated by multiple mechanisms. , 1991, Reviews of physiology, biochemistry and pharmacology.
[8] C. Fisher,et al. Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. , 1991, The Journal of surgical research.
[9] S. Schreiber,et al. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Condorelli,et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. , 1991, Journal of immunology.
[11] T. Starzl,et al. FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION , 1989, The Lancet.
[12] T. Starzl,et al. Renal transplantation in baboons under FK 506. , 1989, Transplantation proceedings.
[13] H. Shimada,et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. , 1989, Transplantation.
[14] G. Remuzzi,et al. Renal vascular and thrombotic effects of cyclosporine. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] T. Rimele,et al. Interaction of neutrophils with vascular smooth muscle: identification of a neutrophil-derived relaxing factor. , 1988, The Journal of pharmacology and experimental therapeutics.
[16] A. Grace,et al. Cyclosporine A enhances platelet aggregation. , 1987, Kidney international.
[17] P. Friend,et al. FK-506 in experimental renal allografts. , 1987, Transplantation proceedings.
[18] H. Sharma,et al. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. , 1985, American journal of surgery.
[19] T. Lerut,et al. THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS , 1985, The Lancet.
[20] R. Griffiths,et al. The effect of 6‐oxo‐prostaglandin E1 on human platelet aggregation in whole blood in‐vitro , 1985, The Journal of pharmacy and pharmacology.
[21] J. Feehally,et al. Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[22] T. C. Jones,et al. Pathology of Laboratory Animals , 1978, Springer New York.